Semaglyn vs Wegovy India in India — molecule, dose, price

Semaglyn vs Wegovy in India

This page is a structural comparison between Semaglyn and Wegovy India — it is not a prescription, a recommendation, or a substitute for clinical advice. Both brands contain the same active molecule, semaglutide, a once-weekly GLP-1 receptor agonist. The differences sit mostly in who manufactures the pen, which doses are listed in India, and what the pen costs at Indian pharmacist counters.

Semaglyn is the Zydus Lifesciences brand of semaglutide, launched in India in 2025. Wegovy is the Novo Nordisk brand, the originator semaglutide product, available in India through Novo's authorised distribution. Because the molecule is identical, expected effects and side-effect profiles overlap heavily — the semaglutide side-effects guide applies to both.

For current Indian rupee pricing on either brand, see /price. To understand how the weekly dose is stepped up over months, see /tools/titration. To check whether a specific brand fits the scenario your doctor described, use /check.

What is structurally the same

At the molecule level, Semaglyn and Wegovy are the same drug. Both deliver semaglutide, a GLP-1 receptor agonist that the label describes as working by slowing gastric emptying, supporting satiety signalling, and modulating insulin response.

Because the molecule is identical:

• Mechanism — Both act through the same GLP-1 pathway, as described on the respective product labels.
• Titration cadence — Both follow a stepwise once-weekly schedule, typically starting at 0.25 mg and stepping up roughly every 4 weeks toward a maintenance dose. See /tools/titration for the structural schedule.
• Side-effect profile — Patients on either brand commonly report nausea, early fullness, constipation, or reflux during titration, as described in the semaglutide side-effects guide.
• Administration — Both are subcutaneous injections, taken once weekly on the same day each week.
• Regulatory pathway — Both carry CDSCO approval for their indicated use in India.

In other words, the clinical scaffolding is shared. The differences below are about brand, supply, and price — not about how the drug works in the body.

What is structurally different

The meaningful differences between Semaglyn and Wegovy in India sit in three places: manufacturer, availability, and price.

Manufacturer. Semaglyn is manufactured by Zydus Lifesciences, an Indian pharmaceutical company headquartered in Ahmedabad. Wegovy is manufactured by Novo Nordisk, the Danish originator of semaglutide. This is the same molecule made by two different companies with two different supply chains into India.

Availability across Indian pharmacy networks. Wegovy India launched through Novo Nordisk's established distribution, and stock at aggregators like Apollo, Tata 1mg, Pharmeasy, and Netmeds has varied by city and by dose strength — higher strengths (1.7 mg, 2.4 mg) have historically been the most supply-constrained semaglutide doses globally. Semaglyn, being a domestically manufactured brand, is positioned to expand availability across Indian Tier-1 and Tier-2 city pharmacist networks. Actual stock on any given day depends on the specific pharmacist; patients commonly report checking two or three aggregators before locating a specific dose.

Price. Indian retail pricing differs between the two brands and shifts month to month. Rather than freeze a number here that goes stale, the live ₹ ranges for each dose strength of both Semaglyn and Wegovy are maintained at /price. Insurance reimbursement in India for GLP-1s remains limited, so out-of-pocket cost is usually the deciding economic factor — your doctor and pharmacist can confirm what applies to your specific case.

Pen design and packaging also differ between manufacturers; your pharmacist can walk you through the device for whichever brand is dispensed.

Questions to bring to your prescriber

If you are weighing Semaglyn against Wegovy, these are useful conversation prompts — not a script, just structure:

• "Both brands contain semaglutide — is there a clinical reason you are leaning toward one for my situation?"
• "Which brand is my regular pharmacist (Apollo / Tata 1mg / Pharmeasy / Netmeds / local) currently able to stock reliably at the dose I will be on in 3-4 months?"
• "What is the realistic ₹ cost per month at the maintenance dose, and does that change if I switch brand mid-titration?"
• "If supply of one brand is interrupted, is it reasonable to switch to the other at the same dose, in your view?"
• "Are there any storage or pen-handling differences I should know between the two?"

You can also use /check to organise scenario-specific questions before your appointment. Final brand selection is a decision to consult your doctor about.